Overview: Hypersensitivity Pneumonitis Screen TestIntroduction: The Hypersensitivity Pneumonitis Screen Test screens for hypersensitivity pneumonitis to diagnose lung inflammation, causing breathing difficulty. Following 2023 ATS guidelines, it uses immunoassays for high specificity, supporting allergy screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected allergic lung conditions.
Other Names: Pneumonitis Screen Assay, HP Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Hypersensitivity pneumonitis screening began in the 1970s with occupational lung disease research. Immunoassay-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Screens for hypersensitivity pneumonitis to diagnose lung inflammation, guides treatment, and evaluates patients with breathing difficulty.
Test Parameters: 1. Pneumonitis Antigens
Pretest Condition: No fasting required. Collect serum at any time. Report exposure to allergens (e.g., mold, bird droppings) or respiratory symptoms.
Specimen: 2-5 mL serum (SST). Centrifuge within 1 hour. Transport in a biohazard bag.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document respiratory symptoms, allergen exposure (e.g., occupational, environmental), or history of lung disease. Include current medications, especially steroids.
Consent: Written consent required, detailing the tests purpose, lung inflammation implications, and potential need for treatment planning.
Procedural Considerations: Uses immunoassays to detect antibodies to pneumonitis antigens. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for allergy screening.
Factors Affecting Result Accuracy: Improper sample handling or contamination can affect results. Recent allergen exposure may influence antibody levels.
Clinical Significance: Positive antibodies suggest hypersensitivity pneumonitis, guiding allergen avoidance or steroid therapy. Negative results may require further lung function testing.
Specialist Consultation: Consult a pulmonologist or allergist for result interpretation and treatment planning.
Additional Supporting Tests: Lung function tests, chest CT, or bronchoalveolar lavage to confirm hypersensitivity pneumonitis.
Test Limitations: Not specific to hypersensitivity pneumonitis; other lung conditions may mimic results. Clinical correlation is needed.
References: ATS Hypersensitivity Pneumonitis Guidelines, 2023; American Journal of Respiratory Medicine, Lacasse Y, 2022.
